Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lotamilast
- Development stage
- Phase 2
- Lead developer
- Dermavant Sciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Lotamilast is a small molecule, selective phosphodiesterase 4 (PDE4) inhibitor developed primarily for the topical treatment of atopic dermatitis. By inhibiting PDE4, lotamilast increases intracellular cyclic AMP levels, which leads to reduced production of proinflammatory cytokines and chemokines, thereby exerting anti-inflammatory and antipruritic effects. The drug was originally discovered by Eisai and later developed by Dermavant Sciences (a subsidiary of Organon). Clinical studies have shown statistically significant improvements in atopic dermatitis symptoms with topical application[1][2][3][4][5][6][7].
- Brand names
- lotamilast
- Other names
- lotamilast
02
Targets
PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on lotamilast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lotamilast.